Recruiting

Testing interferon to prevent relapse after blood stem cell transplant

Plain-English translation of NCT06130579 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing interferon-α, a protein that helps boost the immune system, to see if it can prevent blood cancers (acute myeloid leukemia and myelodysplastic syndrome) from returning after patients receive a transplant of healthy blood stem cells. The study focuses on patients whose cancer cells carry a specific genetic change called TP53 mutation and whose cancer is no longer detectable after transplant. Researchers want to know if this medication can keep the cancer from coming back.

Blood cancers with TP53 mutations are harder to treat and have a higher risk of returning even after successful stem cell transplantation. This medication may help the body's immune system stay alert and catch any cancer cells before they grow back, but it hasn't been fully tested for this purpose yet.

Do you qualify?

You likely qualify if…

you have been diagnosed with acute myeloid leukemia or myelodysplastic syndrome with a TP53 mutation
you have received your first stem cell transplant and have no detectable cancer remaining (checked by flow cytometry within 2 months of transplant)
you are between 12 and 65 years old
you are healthy enough to tolerate treatment (good heart, kidney, and liver function, with reasonable strength and expected survival of at least 3 months)
you do not have severe or uncontrolled graft-versus-host disease (a complication from transplant where donor cells attack your body)

You likely don't qualify if…

you have severe heart, kidney, or liver disease
you have another cancer that requires treatment
you have a severe infection that is not under control
you are unable to understand the study or follow the treatment plan due to brain dysfunction or serious mental illness
you are currently enrolled in another clinical trial

What participation looks like

If you join this study, you will receive interferon-α injections as a preventive treatment after your stem cell transplant. You will have regular visits to your doctor to receive the medication, have blood tests to check how you're doing, and be monitored closely for any side effects or signs of cancer returning. The study will track your health over time to see whether this treatment helps keep your cancer from coming back.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(1 site)

China

Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing Municipality